Provided by Tiger Fintech (Singapore) Pte. Ltd.

COMPASS Pathways plc

4.29
-0.0500-1.15%
Post-market: 4.290.00000.00%19:55 EDT
Volume:2.21M
Turnover:9.26M
Market Cap:401.38M
PE:-2.21
High:4.36
Open:4.35
Low:4.04
Close:4.34
Loading ...

Compass Pathways Appoints Justin Gover To Board Of Directors

Reuters
·
Yesterday

Compass Pathways Appoints Justin Gover to Board of Directors as Dr. Linda McGoldrick Retires

Reuters
·
Yesterday

Compass Pathways PLC expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
28 Jul

Press Release: Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Dow Jones
·
22 Jul

Compass Pathways Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Jul

Compass Pathways Phase 3 trial delivers regulatory win, says H.C. Wainwright

TIPRANKS
·
15 Jul

COMPASS Pathways (CMPS) was downgraded to a Hold Rating at Evercore ISI

TIPRANKS
·
12 Jul

Compass Pathways Management to Discuss Innovations in Mental Health at HC Wainwright Interview

Reuters
·
11 Jul

Psychedelic: Exclusive talk with biotech company Compass Pathways

TIPRANKS
·
10 Jul

Cathie Wood’s ARK Investment buys 29K shares of Compass Pathways today

TIPRANKS
·
04 Jul

Compass Pathways plc Conducted Annual General Meeting

Reuters
·
30 Jun

Compass Pathways weakness a buying opportunity, says Canaccord

TIPRANKS
·
24 Jun

Compass Pathways Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
24 Jun

Compass Pathways results ‘historic first’ for psychedelics, says H.C. Wainwright

TIPRANKS
·
24 Jun

Crude Oil Falls 1%; US Services PMI Declines In June

Benzinga
·
24 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, Eli Lilly, Nuclear stocks

Reuters
·
23 Jun

Evercore ISI Downgrades COMPASS Pathways to In Line From Outperform

MT Newswires Live
·
23 Jun

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Evolent Health (EVH) and Tandem Diabetes Care (TNDM)

TIPRANKS
·
23 Jun

Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial

Reuters
·
23 Jun

Compass Pathways' depression drug succeeds late-stage trial

Reuters
·
23 Jun